- Home
- MIRM vs KEX Comparison
MIRM vs KEX Comparison
Compare MIRM & KEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | KEX |
|---|---|---|
| Founded | 2018 | 1921 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.0B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MIRM | KEX |
|---|---|---|
| Price | $93.69 | $143.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | $115.33 | ★ $137.25 |
| AVG Volume (30 Days) | ★ 702.8K | 630.1K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | 28.92 |
| EPS | N/A | ★ 6.33 |
| Revenue | ★ $19,138,000.00 | N/A |
| Revenue This Year | $26.22 | $4.19 |
| Revenue Next Year | $22.04 | $7.56 |
| P/E Ratio | ★ N/A | $22.65 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.18 | $79.52 |
| 52 Week High | $109.28 | $144.78 |
Technical Indicators
Market Signals| Indicator | MIRM | KEX |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 68.22 |
| Support Level | $85.35 | $107.87 |
| Resistance Level | $98.03 | N/A |
| Average True Range (ATR) | 3.39 | 3.39 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 20.06 | 72.13 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About KEX Kirby Corporation
Kirby Corp is a domestic tank barge operator, transporting bulk liquid products throughout three United States coasts. The Company transports petrochemicals, liquid cargoes, inland waterway systems, and dry bulk cargoes. The Company conducts operations in two reportable business segments: The Marine transportation segment which provides marine transportation services, operating tank barges and towing vessels transporting bulk liquid products, and the Distribution and services segment, which provides after-market service, and genuine replacement parts for engines, transmissions, reduction gears, and power generation equipment used in oil and gas and commercial and industrial applications. The company's revenue is generated from the Marine Transportation segment.